Sinovac
E337018
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Sinovac canonical | 2 |
| Sinovac Biotech Ltd. | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3205352 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sinovac Context triple: [COVID-19 pandemic, majorVaccineDeveloper, Sinovac]
-
A.
Sinopharm
Sinopharm is a Chinese state-owned pharmaceutical company best known globally for developing and distributing inactivated COVID-19 vaccines.
-
B.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
C.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
D.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
E.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Sinovac Target entity description: Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
A.
Sinopharm
Sinopharm is a Chinese state-owned pharmaceutical company best known globally for developing and distributing inactivated COVID-19 vaccines.
-
B.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
C.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
D.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
E.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
biopharmaceutical company ⓘ inactivated virus vaccine ⓘ public company ⓘ |
| collaboratedWith | Instituto Butantan ⓘ |
| conductedClinicalTrialsIn |
Brazil
ⓘ
Chile ⓘ Indonesia ⓘ Turkey ⓘ |
| country | China ⓘ |
| developedVaccineFor |
COVID-19 pandemic
ⓘ
surface form:
COVID-19
EV71 hand, foot and mouth disease ⓘ 2009 H1N1 influenza pandemic ⓘ
surface form:
H1N1 influenza
hepatitis A ⓘ hepatitis B ⓘ influenza ⓘ mumps ⓘ pneumococcal disease ⓘ rabies ⓘ varicella ⓘ |
| developer | Sinovac self-linksurface differs ⓘ |
| focusesOn |
human vaccines
ⓘ
infectious diseases ⓘ |
| foundedBy | Yin Weidong ⓘ |
| hasCEO | Yin Weidong ⓘ |
| hasOfficialWebsite | http://www.sinovac.com ⓘ |
| headquartersLocation | Beijing ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ vaccines ⓘ |
| legalName |
Sinovac
self-linksurface differs
ⓘ
surface form:
Sinovac Biotech Ltd.
|
| notableProduct | CoronaVac ⓘ |
| notableVaccine | CoronaVac ⓘ |
| playedRoleIn | global COVID-19 vaccination campaigns ⓘ |
| productType | inactivated vaccines ⓘ |
| regionServed | global ⓘ |
| regulatoryApprovalForCoronaVac |
Brazil
ⓘ
Chile ⓘ China ⓘ Indonesia ⓘ Turkey ⓘ |
| specializesIn | inactivated virus vaccines ⓘ |
| suppliedVaccinesTo |
Brazil
ⓘ
Chile ⓘ Indonesia ⓘ Turkey ⓘ multiple low- and middle-income countries ⓘ |
| targetDisease |
COVID-19 pandemic
ⓘ
surface form:
COVID-19
|
| targetVirus | SARS-CoV-2 ⓘ |
| tradedAs | NASDAQ:SVA ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Sinovac Description of subject: Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Sinovac Biotech Ltd.